Table 1.
Clinical characteristics of the cohort (n = 200)
| All | No T2D (n = 129) | T2D (n = 71) | |
|---|---|---|---|
| Age (years) | 69.3 (SD 8.6) | 69 (SD 8.8) | 70 (SD 8.3) |
| Sex–Males (%) | 134 (67%) | 86 (67%) | 48 (68%) |
| Smoking- current/non smokers (%) | 65/40 (33/20) | 44/24 (34/19) | 21/16 (30/23) |
| BMIa | 27 (SD 3.9) | 26 (SD 3.7) | 28 (SD 3.9)*** |
| Degree of stenosis (%) | 90 (IQR 80-95) | 90 (IQR 80-95) | 90 (IQR 75-95) |
| Hypertension (%) | 147 (74) | 94 (73) | 53 (75) |
| hsCRP (mg/L)b | 3.9 (IQR 2.0-6.6) | 3.8 (IQR 2-6.7) | 4.2 (IQR 1.9-6.6) |
| HbA1c (mmol/mol)e | 44 (IQR 38-56) | 39 (IQR 36-41) | 56 (IQR 47-66)*** |
| Plasma lipoproteins (mmol/L) | |||
| Total cholesterol | 4.4 (SD 1.1) | 4.6 (SD 1.1) | 4.2 (SD 1.1)* |
| LDLc | 2.5 (IQR 1.9-3.2) | 2.6 (IQR 2.0-3.3) | 2.2 (IQR 1.6-3.0)** |
| HDLd | 1.1 (IQR 0.9-1.3) | 1.1 (IQR 0.9-1.3) | 1.0 (IQR 0.8-1.3) |
| Triglycerides | 1.3 (IQR 1.0-1.8) | 1.2 (IQR 0.9-1.7) | 1.6 (IQR 1.0-2.1)** |
| Blood glucose lowering treatment, n(%) | |||
| Life style changes | 11 (6%) | – | 11 (15%) |
| Oral glucose lowering treatment | 37 (19%) | – | 37 (52%) |
| Insulin | 22 (11%) | – | 22 (31%) |
| Insulin and oral glucose lowering | 12 (6%) | – | 12 (17%) |
| Blood pressure lowering treatment, n(%) | |||
| RAAS inhibitor | 101 (51%) | 58 (45%) | 43 (61%)* |
| Beta blocker | 98 (49%) | 59 (46%) | 39 (55%) |
| Statin treatment, n(%) | 164 (82%) | 100 (78%) | 64 (90%)* |
Categorical variables are expressed in total amount and percentages. Continuous variables as median and interquartile range (IQR) or mean and standard deviation (SD)
aBMI Body mass index
bhsCRP high sensitive CRP
cLDL Low-density lipoprotein cholesterol
dHDL High-density lipoprotein
e HbA1c hemoglobin A1c, was available for 62% (n = 124) of the cohort. Hypertension defined as: anti-hypertensive treatment or systolic pressure > 140 mmHg. Level of significance between no diabetes and T2D patients is marked by *p < 0.05, **p < 0.01 and ***p < 0.005